Salk Institute

Technologies Available for Licensing

Non-Nucleoside Reverse Transcriptase Inhibitors

Inventors: Daniel Elleder, John Young, Thomas Baiga, Joseph Noel
Potential Uses: HIV, Infection, Virus, Drug Development
Novel NNRTIs, compounds and pharmaceutical compositions for reducing HIV infection and replication.

Resistance of the human immunodeficiency virus (HIV) to HIV drugs has always been a major cause of treatment failure, leading to the use of combination therapy employing multiple anti-HIV agents, each usually having a different activity profile.

The introduction of HAART therapy (Highly Active Anti-Retroviral Therapy), for example, has resulted in a significant reduction of morbidity and mortality in those HIV patients receiving it. HAART involves various combinations of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). Current guidelines for antiretroviral therapy now recommend triple combination therapy regimens for initial treatment.

Unfortunately, multi-drug therapies do not completely eliminate HIV, and long-term treatment usually results in multi-drug resistance. Half of the patients receiving anti-HIV combination therapy fail to respond fully, mainly because of resistance of the virus to one or more drugs used. The resistant virus is also carried over to newly infected individuals, who as a result have severely limited therapy options.

Recently Salk Institute scientists identified a novel lead compound: a non-nucleoside reverse transcriptase inhibitor (NNTRI) that substantially reduces the activity of HIV-1 reverse transcriptase, thereby reducing HIV infection. This NNTRI also acts synergistically with one particular NRTI, zidovudine (or AZT), the first drug approved for the treatment of HIV.

Structural Activity Relationship (SAR) analysis has identified additional, more potent derivatives of this compound, and experiments have confirmed their efficacy against wild-type and existing drug-resistant HIV-1 variants isolated from patients. The technology disclosed in the pending patent includes novel NNRTIs and compounds that can substantially inhibit HIV infection and replication and can be used in combination with other retriviral inhibitors. Also described are pharmaceutical compositions, prodrugs of the compounds, and methods for their creation, preparation and use.

Salk No: S07014
Patent Status: International Patent Application published as WO 2009/061856
Publications: None to date
License Terms: Exclusive and Non-Exclusive Licenses Available
Contact: Michelle Booden, Ph.D., Director of Licensing, 858.453.4100 x1612, mbooden@salk.edu

Get Involved

Sign up for our email newsletter

Fill out my online form.
Contact
Salk Institute for Biological Studies
Street: 10010 N Torrey Pines Rd
City: La Jolla, CA 92037
Email: webrequest@salk.edu
Phone: 858.453.4100
Charity Navigator Rating
  • Salk Twitter
  • Salk LinkedIn
  • Salk Facebook
  • Salk Instagram
  • Salk Google+
  • Salk YouTube
  • Salk RSS Feed
© Copyright 2014 Salk Institute for Biological Studies | Privacy Policy About Scientists & Research News & Media Events Support